Author of

• 15558

  +

  P3.07 - Poster Session/ Small Cell Lung Cancer (ID 223)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Small Cell Lung Cancer
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15559

    +

    P3.07-001 - Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Small-Cell Lung Cancer (SCLC): A Single Center Experience (ID 924)

    09:30 - 09:30  |  Author(s): B.I. Hiddinga
    • Abstract
    • Slides

    Background:
    In small-cell lung cancer little is known about harboring an ALK translocation [1, 2]. The aim of this study was to investigate the prevalence of ALK expression and rearrangement in patients with SCLC.
    
    Methods:
    In this retrospective series, archival tissue from 17 treatment naïve patients with SCLC and neuroendocrine tumors was analyzed to detect ALK expression by immunohistochemistry (IHC) in all samples. Cut-off value for positivity was similar as in non-small-cell lung cancer (NSCLC): focally strong staining of the tumor cells Fluorescent in-situ hybridization (FISH) with Vysis LSI ALK probe was performed in the IHC positive cases [3]. The ALK FISH positive cases were submitted for exome sequencing (NGS) (Illumina MiseQ).
    
    Results:
    Of the 17 patients 9 were male and 8 female. Of these 17 patients 12 had a SCLC, 3 a neuroendocrine tumor, and 2 a neuroendocrine carcinoma. Three specimens could not be analyzed. Six of 17 specimens were ALK IHC positive, of which one neuroendocrine tumor, one neuroendocrine carcinoma and 4 of the SCLC.
    
    Conclusion:
    The IHC expression of ALK suggests a possible role of ALK-TKI in the treatment of SCLC. Mature FISH and NGS data will be presented at the meeting.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.